In this video interview, Gaynor Anders, chief delivery officer at Trialbee, explains why the industry's protocol-centric recruitment model has persisted so long and what a shift toward programmatic, ...
In today's ACT Brief, we examine how FDA's single pivotal trial shift raises recruitment and retention stakes, why FSP should ...
In a recent video interview with Applied Clinical Trials, Rob DiCicco, vice president of portfolio management at ...
FDA proof-of-concept trials with AstraZeneca and Amgen validate continuous data transmission and signal detection, setting ...
In today's ACT Brief, we recap key themes from DIA 2026 on operational priorities and regulatory shifts, examine ...
In today's ACT Brief, we examine what the FDA's real-time oversight initiative demands of sponsors, why clinical data ...
Protocol design does not struggle in the protocol. It struggles in the transition to trial, when assumptions embedded in the ...
In today's ACT Brief, we examine quantified reductions in trial visits through selective safety data collection, why protocol ...
Enrollment decisions hinge on trust, hope, and fear, and logistical burden reductions rarely overcome affective barriers without trusted mediators who validate credibility and safety.
In this Q&A, Liz Beatty, co-founder and chief strategy officer at Inato, discusses how real-time patient data is reducing non-enrolling sites, why sponsor-specific technology remains the biggest ...
AI-enabled systems medicine could influence which populations are selected for trials, how biomarkers are validated, how products are positioned, how evidence is generated after launch, and how value ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results